Any ideas anyone?

Time this one came to the top, up 25.5p so far today on news of a deal with Unilever.

Nice bit on PYM here, reinforces todays announcement of the deal with Unilever.http://news.bbc.co.uk/1/hi/business/4098493.stm

A full page article in Daily Mail today, not in the business section, more inclined towards health and dieting, but good exposure.

What no interest in PYM - as it goes from Cold to Hot and Cold (also)?

The Profit news today may not have impressed the Market (sp down) but it shows how a Pharma can swing from Loss to Profit provided the product works - which most here believe.

There are problems IMHO, on the horizon (competition from related plants) -and for that reason I won't make this a large holding, but it might take-off and then it would be a pity to miss the fun.
I hold, having taken up the Rights Issue, although it was a bit pricey.

I'd like to add that recent event with the company's broker have NOT helped the sp ( now visiting sub 90p), as Animal Rights Activists have (it would seem) created something of an own-goal by targeting Phytopharm, whose medicines are already tested on man.
It may be that there will be need for animal testing, but this applies to any product that is "consumed" by humans - it's simply a necessary step to getting EU approval.

I have taken this low sp to increase my holding: the Rights issue was a bit pricey (IMHO) - so this reduces the average.
.
Often it's "bad News" that concentrates Market-perception of a company; we check their figures ask questions and so on - so whilst there "could" be over-reaction in respect of the sp, it is likely to be nearer fully-valued than a few months ago when the City was trying to off-load a Rights Issue.........invariably there is a gentle up-list in price just prior to the ann.

just been tipped in SHARE Magazine under their cover article "Back in the race".
Unilever is struggling still with SlimFast and I dont see their sales taking off after their tie in with PYM. Let it be IMHO

If you have read the Shares article you'll know that Phytopharm is "due to receive Phase 11 data from it's trials for Alzheimer's drug Cogane at the end of the year, there is plenty of opportunity for these share to recover significantly".

Cogane does sound to be a wonderdrug but Shares may be unaware that a recent study by NICE decided that treatment of Alzheimers was not cost effective and has decided to ban all prescriptions of drugs to treat this disease in new patients. The Alzheimers Society has put up a brave defence but at the moment it seems unlikely to alter the fact that the government wants to save money and treating a disease that affects mostly the elderly, in their view, is a good place to start.

I wonder that we shouldn't be so narrow in our view - if the drug works there is a Market (it may take some finding) - generally in the US where the drug Market is 10x UK size.
It is difficult to understand why the sp has stuck to the 85/90p range, but the same thing happened with Cobra - - sales slumped in line with expectations, yet the Market thinks "this is dire" and the sp fell from over 1 to close on 25p - picking some of these was a no-brainer and reading their annual Report (1year on)shows the US willing to use their services. Hopefully [CBF] Management will have learnt their lesson = Don't worry the Market.

PYM maybe has something to learn, but we'll be seeing a gradual improvement in sp since I doubt there is any further "bad news" and gradually folk will recognise this isn't a 1-product co. (however, the market for Hoodia is being queered IMHO by July reports that Kings College (is it?) has discovered a way to cheat the stomach) - KC are in early trials - so aren't they re-inventing Hoodia? The difference being, Hoodia has been trialed in humans for 100's of years [admitedly not western clinical] but if you get to a well to drink, as others are leaving with their water bottles full, you'd be tempted to slake your thirst; I would.

Finally, this Government may be further cheating the elderly (like the tax-credits on dividends, etc.) but that doesn't mean there won't be a UK demand, provided PYM can get them early enough - so they can make an informed choice!
/Regards.

I'm tempted to buy. Just not sure if all the bad news is in the price - losing their Japanese contract, their broker etc.

Even if the UK gov will not oblige future Alzheimers patients, USA will, as seen yesterday in the deal with Regentherapeutics.

More buyers than sellers today.

any views on this

My position hasn't changed, but telephone the company for the latest news - I think the Animal rights issue is still a concern (although I fail to see why PYM is involved, the so-called association with HLS is really pretty thin IMHO - these activists need culling unless they adopt purely peaceful tactics - maybe the 90days would help, but I suspect there is no Police activity until it become a National Issue)
I suspect this is at the heart of the sp fall.......but new investors can still buy for ISA - that affords some protection I guess.....but the loss of a Broker/adviser is really not an issue - it just makes other investors more nervous.
Obesity is likely to kill many people with the knock-on effect on families - so the success of their No1 product is (almost) G'teed - what hasn't been demonstrated is how much PYM will make (in cash). I have a few ini an old PEP at about 90p so almost evens....

Where next any one

I'm not sure what's holding this back - at current levels they are historically as cheap as _ . However, their time to Market seems to be getting longer (or punters like myself got too excited) - they have a vetinary product that's looking good (ie cash generating as soon as the boxes are printed) - and they have an obesity product that is soon to undergo trial in its final form (a Unilever food, I understand)
although real-sales are unlikely before 2008....The "risk" with this type of product is munute IMHO - Unilever don't go with duds. Of course we have to wait and see what Royalties roll in.....
...and there is an asthma product moving along - anyone wanting a sure-fire stock to tuck nto an ISA - look no further.
Yes I do hold, from somewhat higher - and have bought recently at 50p - well, let's hear from others - what's the problem?

problem is with small cap stocks when newsflow fades the stock ticks slowly south. players become stale. if a stock is worth holding,it must equally be worth buying! bought at a pound or 50p pym is good value. this stock i consider to be my least speculative play hangon hangon!

PYM is really cheap at the mo... big money to be made, i bought 4000 on monday on an opening low, already 8.9% up... strang that the price was dropping on monday even though there were a lot more buys than sells... is there something i do not know... Or is it just because the market makers had too many shares, and sold them off cheap?

Still think that these shares are really hot... They have had a lot of bad news which has created bad sentiment.... Always good to by on bad sentiment, since the shares have a much higher real value... THESE SHARES ARE REALLY UNDERVALUED

I fear you are telling us what we want to believe....where is your evidence that these shares are hot (and comfirm you mean "good to buy now")...please?
/
Over recent weeks the sp has stabalised about the 50p mark, but that's becasue there is cash to last a little longer and there is every chance they will generate some income, thereby avoiding the need to tap the Market......but "hot"? I fear not - more like "not stone cold".
/
Should the worst happen and they need more cash ( This might be for another line of product/research) -I can see retail investors, like thee and me, being diluted and it is this fear (I presume) along with expectation of delays until 2008 that is holding-back Buying......your investment is fairly safe IMHO, but I don't see this high temperature, please explain.
Many here will have been nursing losses from 2.

I am not a market expert, but PYM turnover jumped up early november. Do you think interest might be increasesd from Hoodia project? as soon as more info comes through....

PYM did a Rights Issue last year so they have some on-going cash - and there was a Unilever deal as well as a vetinary product (could this be the confusion for Animal Rights activity?) - this product is FOR animals to improve their life against itchy skin - which I understand has no alternative cure.....so there.....DYOR as ever.
/
SP fallen today on little News (indeed PYM is reccommended for anyone with a hearing problem).......but it's darn close to a 12 month Low - and that was the lowest it's been for ages.
/
I suppose I have to ask myself Do I feel Lucky - is the Co about to fold? .....Arrgh.
- Still, I hold in hope......maybe being a little silly, eh?
Currently 42p-ish

Hoodia - I've looked at Slim-fash (google) and it is a Unilever "brand" so it's possible this is the brand that will take the hoodia product......but there is no mention of this by Unilever.......and other related sites don't mention hoodia.....so does anyone know for certain where we should look for Unilever info on Release Dates, product prices etc?

brief news article regarding appetite suppressants. from extreme surgical methods to a new product shortly to be available from unilever which induces the sensation of afull stomach. re:lbc 1152 thur 23 am. assume this is hoodia

Share price seems to be falling still...

Excellent article on this site. At least they talked to the company before writing.

Just need an email address to register.

Phytopharm:
Is Phytopharm damaged goods?
(Mar 2006)

In theory Phytopharm has an interesting business plan - develop pharmaceutical drugs based on research into plant extracts from which drug candidates can be purified

http://www.proactiveinvestors.com

some good news today... but will it hold up this time, this share likes to break north very quickerly, the same way it falls... keep an eye on these ones

I had to buy in on these ones... feel the time is right. Results will be out on the Monday 8 May 2006. There will be some sepeculation that the results should be good, possible some profit. This was the recent news release;


Under the terms of the agreement, Phytopharm and Unilever are collaborating on a
five-stage research and development programme of safety and efficacy studies
with a view to bringing new weight management products to market. As part of the
agreement announced in December 2004, Unilever committed to initial payments of
approximately 6.5 million for the first stage and for the second stage have now
committed to a further 3.5 million out of a potential total of 21 million in
payments to Phytopharm. In addition Phytopharm will receive an undisclosed
royalty on sales of all products containing the extract. Unilever is also
managing a separate agronomy programme and supporting the international patent
programme for the products.

Phytopharm licensed the global patent rights for the extract of Hoodia gordonii,
a plant indigenous to South Africa, for incorporation into weight loss products
from the South African Council for Scientific and Industrial Research (CSIR) in
1997.

I would welcome other peoples comments on this company... Shares mag has made a buy recommendation

these shares are booming, I am not a glory hunter but think i was right about there move north, I am going to stock up

up 13% today

Also large x trade went through today, 2,459,817 shares in this one deal... past experiance tells me that whenever a large x trade goes through on a penny share it is a good signal... we will have to wait and see but i feel this one should be in your watchlist... there is a separate thread about large x trades, but can not remember its title, sorry..... comments?

http://www.moneyam.com/TradersRoom/posts.php?tid=9156#lastread

Here you go...

Mega...

These guys are booming, feel they could boom up to 145p... big profit availible.... am I talking to myself... Tonker

Phytopharm PLC has appointed Teather & Greenwood Ltd as joint financial adviser and stockbroker.

Hope you are right TONKER I need 102p to break even, now they have a broker they have a chance.

Feel things are changing for this company, sp is really moving and i feel that there is a lot more to come.... As I said earlier think the results that will be out on the 8 may will be good... lets hope they ramp up! It is a shame other people are not as interested in these type of shares, feel that oil/mining shares dominate these threads... I can only hope people have been reading these posts and have taken action, for i feel that it will be a little late now to make a super profit (but not too late to make a modest 50%)!!!
Regards Tonker
NB. I am a share holder in this company... my opinion will be biased, but I am fundermentally honest...

still going up...

Tonker, I hold also - from about 1 average; here's some hope-bias!
.......The problem with PYM was timing - they were caught up in the Dot-com fiasco and had a huge value - this was always a long-term bet and as far as I see it, they are delivering slowly. The Doggy deal is a regular income and the food-suppliment (if all goes well) should be massive for a small-cap company.
The Results are unlikely to give us anything unexpected, I hoping..... although some further deals would be nice.
PYM always did look super-value but there is no g'tee - whereas Oil-stocks are heading North because Oil is a commodity and that's is unlikely to drop - even $50/b looks cheap "now".
The other problem for PYM was the animal activists - "--so what it's tested on animals? It's a dog medicine, what would you like it tested on, Eh? .."
This also caused the sp to fall, since there was no regular income and folk worried there might be pipeline disruption. The loss of their broker didn't help, but they were not essential to the business, or listing, I understand.
PYM is fully ISA-able and at current prices (say sub-50p) look to turn a decent profit, for the patient.

Thanks hangon, thanks for your comment, am hoping for a quick short term profit with these ones, have already made 45% on these ones and am looking to get out soon.. could resist waiting to hear the results this monday... maybe some more good news as well... as I have mentioned earlier that large x trades in penny shares normally means a good signal for the SP.... now some might say that the new broker will be the good news but there could be more

Quite a bit of Good News has washed-away the market's recent opinions about PYM.
I can understand you wanting to bank a profit (no harm, etc.), but if the pipeline of Royalties is real, then you are throwing away a yield that could be a considerable benefit. Something to consider - for example LLOY is about 7% yield, right now, but anyone taking a punt when the sp was just over 5 will be reaping a yield near 10% (on their investment) - there aren't mny legit places for that return and if there is a TO (for LLOY) a decent cash benefit too.
/
I've been reading stories that BigPharma is starting to worry about their futures - with Patents running out and little to replace them. In the past the "generic" market was a bit jokey and Doctors kept prescribing the old "brands" (since they wern't paying for it). However, now things are different and generics are seen as "good" - that's why I'm holding Bioprogress - that have started to market their "alternative delivery" not just to Big Pharms (=Patent extension), but also directly into the secondary market by offering ingenious packaging/delivery - like PYM they aren't there yet.....but if they succeed then they could become Big Pharma as (BP's) fortunes wane - there is no g'tee that the likes of Glaxo will continue to dominate, say in the next 20 years.
- Buying out PYM and BPRG would seem to me to be a very cheap option for senior Staff at Glaxo, that wish to retire comfortably.
(above is not intended to be a rant, or ramp - I'm not buying these, just holding)

We(holders) are in a position where but for a real accident, these companies are about to move into the early-stages of being BIG ( needs abt. 5-years of growth ). By then they will have regular incomes and the mind-set to continue formulating new products - then by about 20years hence, they may lose their edge, like Big Pharma - and some new development will attempt to topple them.

What's certain IMHO, is my holding in SKP (skypharma) will remain in the jam-tomorrow position they've held for so long. Micap[MIC] may be paired with them, soon, also. However both are in "alternative delivery" and such techniques could (the watch-word) mean that failed drugs suddenly become attractive, FWIW I would support a refinancing of SKP/MIC if they would buy-up recently failed patents, where the fault was in the delivery. New-delivery might (a big guess!) be a way to make fortunes in health esp as the World pop. ages........
Wow!
I must lie down, now.

PYM is on the up, with the doggy-cream launched and sp rising albeit slowly from 40p to wisker near 60p - that's a 50% rise which is GOOD in anyone's money.

Some way to get to 1 and another 50% increase will get harder, as the sp reaches "fair value" - which many hope is just a tad over 1.

It would be nice to know there are other products in the pipeline - that's my worry; - but I'm happy with my 40% profit, allowing for my timing error and spread.

Broker T&G initiating coverage with buy and price target of........120p . Should get the share back to above 50p even in these markets

Here comes the move , some sniffy buying after report digested ??

55p bid --- nice 23% return --- moving to LRL for similar

From Boxing Day's Independent:

Cactus that promises to curb the appetite


By Cahal Milmo


Published:26 December 2006








A multi-million pound race between the world's biggest food companies is under way to tackle the global obesity epidemic by producing the first clinically-tested "satiety pill".


Three conglomerates - the Anglo-Dutch firm Unilever, France's Danone and Kraft in America - are researching compounds to achieve the hallowed goal of inducing people to eat less by suppressing their appetite.


With 300 million people worldwide rated as overweight or obese, the annual global cost of treatment and economic loss from the epidemic is now 100bn.


Scientists are increasingly placing their hopes in a range of natural substances which have the effect of duping the brain into "satiety" - the feeling of a full stomach. In the last 12 months, patents have been given appetite-suppressing extracts including Korean pine nuts and chicory roots. But at the head of the race to cash in on the 3bn worldwide market for dietary control products is Hoodia gordonii - a spiny cactus, which takes five years to mature in the Kalahari desert.


Hoodia contains a secret weapon - a compound known as P57 which has been isolated by a British bio-technology company, Phytopharm, and is now at the heart of a 21m research scheme funded by Unilever.


Phytopharm announced last month that it was making good progress in clinical trials of P57. The cucumber-like core of the Hoodia has been used for centuries by indigenous San tribesmen to stave off hunger pangs. They eat it on long hunting trips.


Unilever has struck a deal with the San to pay the tribe a royalty from the sales of any product containing P57 to be used in a social programme.


Phytopharm, which will also receive a royalty on sales of all products containing its Hoodia extract, warned last month that it was talking with authorities to curtail the sale of "Hoodia" products on the internet which claim to cause weight loss. Unilever is working to launch a range of "hunger buster" products based on Hoodia in 2009.


Phytopharm found that the compound closely mimics a natural substance in the body which sends a satiety message to the hypothalamus - the part of the brain that controls appetite.


Trials have shown that those taking P57 can cut their consumption by as much as 1,000 calories per day. The recommended calorie total for an adult man is 2,500 per day and for a woman, 2,000. A Unilever spokesman said: "We don't want to put our name to something that is not backed 100 per cent by the science behind it. We are now satisfied that the product works and has the potential to help with weight management."


The cash and energy being pumped into Unilever's project is mirrored by its rivals. Danone has patented new types of dietary fibre which slow the passage of food through the digestive system, making people feel full for longer. Kraft is working on a special form of starch which resists being broken down by the body, again designed to create the sense that the stomach is full.


But a senior executive with one conglomerate told The Independent: "Satiety has the potential to be one of the biggest earners of the next five years."


Many of the substances, including P57, work by affecting a mechanism in the ileum, part of the lower intestine, where the presence of fat triggers a response of satiety to the brain.


This "ileal brake" is triggered or mimicked by the compounds by disguising the fat molecules until they reach the ileum. In one case, the body is convinced it has consumed 500 calories when in reality it has had just 190.


However, according to Gary Frost, professor of nutrition and dietetics at Surrey University, humans have a "squirreling" instinct which encourages them to eat to excess in preparation for times of food scarcity. "There is a sense that for the company or companies that can isolate a proven appetite suppressant, there is a market waiting that would entail the vast majority of the population," he said. "It is a glittering prize but a controversial one - can you confidently say that one food will halt your desire for another?"


Neville Rigby, spokesman for the International Obesity Task Force, said: "The key to tackling obesity is eating decent food and balancing your calorie intake with the amount of energy you burn. There is no magic bullet."

Moving up over last few days, is this because more good news is likely? I suspect not, since the co just ann. their canine product is going World-wide (soon), but it might be anticipation of income towards the end of 2007.

The previous wrier is dismissing the appetite suppressant by sugesting humans will resist any attempt...etc.
It is a "magic bullet" IF you can find that part of us that says we are full - but I suspect we may see a situation where our appetite is "remapped" so that the hunger is overcome at lower levels of satisfaction. The problem fat people have is that they have stretched their stomachs - so more food is needed to reach the point of satisfaction....by allowing the satisfaction to come sooner (the amount based on their intake of this replacement food) they will be able to let the stomach reduce in size so they can find goodness in "healthier" foods. Presently they crave fats because these produce the "satisfaction" that we humans crave. It is this "remapping" that I'm hoping is at the foundation of the hoodia commercial product.
(That product has to have a balance of nutrients so anyone that switches to it will remain "balanced" at least until they can eat normally.)
Of course the key to obesity is ...to eat less (to match your exercise, etc), -but this is the goal...not the route. Without help, the route would be extremely painful as few of us can reduce our intake ( say by one third), .....even though it would "probably" be good for us.
The key, IMHO for normal people is alway to keep a little bit of hunger present, that way you know you haven't overdone it. However, what served past generations (the storing of fats for winter) is not needed, since we have food in the shops all-year.
I hold PYM and hope their products are successful, but the market over-hyped the SP until 2005, since when its been under 1 (and often under 50p) which is right IMHO for a co. with no turnover.
I suspect the "biggie" is a few years away, but now might be the time to tuck away.

For whatever reason this has moved up 20% in two days on relatively low volume.
Nearly bought at 40p (bugger!!) but will keep an eye on this, maybe another milestone payment is due or announcement about a product launch?

No need to worry - you can pick them up far lower (32p today) - it seems that late October has brought on the Spectre of Options - - - laughingly said to be part of the incentive-plan - - - So where is mine? - all I recall is the sp slipping and prior promises left hanging in the air.
This sp was well over 1 not that long ago. Promises of a cure for obesity looked good, but they were reluctant to sell anything, preferring to do a deal with Big Pharma - ah yes, but I suspect BP found the stuff was too expensive, so they had to do a deal with a "foodie" - - and as far as I know that has been very silent.
Grr.

EDIT. Dec.'07:-
I read that things are progressing, but there seems to be little interest here/elsewhere, as this is a long-time event. The dog-treatment is doing OK and the Food additive looks to be undergoing trials, still.

Not much to report beyond the EDIT of Dec 07.....
-Apart from a fundraising at 22p - quite dilutive! (March 2008).

-and within two months we are seeing the sp matching the Discounted Rights Issue......Oh no, is this another bad investment?

MM's push the sp up 3% on zero volume - 17p to buy - Will I?

Hey-Ho and up they go,
Ho-Hum and Down they come.

Hello, PYM,...
Let's know what you are doing with this( Rights issue at 22p), money - is it holiday-break time, I wonder?

PYM received notice of termination of employment contract
from Daryl Rees, Chief Executive Officer,
and Piers Morgan, Chief Financial Officer.
(sp is down 15% on zero volume - MM's playing with us.)


- FWIW - To lose one Director is carelessness, but TWO is a disaster.
CEO and FD both walk - could this be the beginning of a real bust-up at this serial-loser?
+They had 22p(Rights) from shareholders and this is now 9p - Grr.
EDIT (17Nov08)- 7.5p to Buy today after a sale of 3k, it falls 25% - then, later Buys=3k qnd it's up to +30% - How can this Full-Mkt stock move so much on just 3k deals?I Guess at these levels this is a Bargain, but I'm fearful this Management has been smoking the stuff (-oops!).
EDIT(19Nov08)- up 25% on zero trades -Huh!
EDIT(9Dec08)- down 20% on Sales just over 1k.
EDIT(10Dec08)- up 13% on zero volume, [4.5--6.5p]
EDIT (30Jan09) - down 14% on zero-volume (3.75p,mid. what a Shower!)
EDIT(20May09) - up on general Market rise; then down today - losses increase - isn't this a hopeless business (despite the Fido-treatment.).
EDIT-(12Jn09)- Recent results look pertty dire - in effect a tiny turnover and a mildly staggering loss! Yikes! What it is saying is that for the last 10-years we've been asleep, hoping something would turn up. What I continue to wonder about is why Hoodia isn't a stonking success... does it taste really foul? - - - or is it easy to "overdose" on it? - - What would be the OD effect? - surely any medicine causes difficulties if you take all the tablets in one hit?
EDIT(8Jy09)-a Buy of 225(plus charges) pushes the sp 11% - Oh deary.
EDIT (13Oct09)-rise of 22% on No News, yet Buys are 8x Sells, for a change.
EDIT(14Oct09)- Ah yes, Drug success, which we only know today.[=up 330%!!! on Buys barely 2x Sells, IMHO this is MM's ...making Hay].#
EDIT (15Oct09)-oddly the sp is marked down, yet the Buys are nearly 1/3 more than Sells...Odd.
EDIT (19Oct09)-Buys?Sells evens, yet MM's push sp 11%, prob on Broker 50p assumption . . . er? [ 24p today]

Studies offer hope for Phytopharm Parkinson's treatment

KBC Peel Hunt doubles Phytopharm TP to 50p on Cogane results, keeps buy

WOW---who was lucky enough to be holding this one today! Looks as though all pxs fans have found another star and it can go into your isa. I'm in for a few before the US open. It might fall back but the treatment/success looks good.

Its the first 'doubler' in a day I've had since those heady tech days!

UPDATE: Phytopharm Shares Soar On Early Cogane Promise





(Adds detail on drug's potential, analyst comment, stock rating)


By Jason Douglas
Of DOW JONES NEWSWIRES

LONDON -(Dow Jones)- Shares in drug maker Phytopharm PLC (PYM.LN) more than quadrupled Wednesday after it said its experimental Parkinson's disease treatment Cogane showed promise in two early-stage studies.

Phytopharm said a study funded by the Michael J. Fox Foundation, a Parkinson's research charity founded by the Hollywood actor, showed use of Cogane led to a 43% reduction in Parkinson's symptoms among monkeys given a drug to replicate those symptoms.

This type of study in monkeys is considered the gold-standard model for assessing experimental Parkinson's medicines before testing them on humans, according to Jonathan Brochtie, a senior scientist at Toronto West Hospital who conducted the study.

"Cogane holds the promise to be the first in a new class of treatments," he said.

A second study in a small number of healthy human volunteers showed Cogane was safe and also demonstrated some evidence of pharmacological activity, Phytopharm said.

The firm now plans a phase II clinical study of Cogane in patients next year.

At 1435 GMT, shares in Phytopharm were 18.87 pence higher at 25 pence, making it the biggest riser in a 0.5% higher FTSE Fledging index.

Cogane is far from starting the big human trials needed to win regulatory approval. But Paul Cuddon, an analyst at Phytopharm's broker KBC Peel Hunt, said the results of these trials show real promise because this type of primate trial has been shown to be "highly predictive" of a similar response in humans. He rates the stock "buy" and Wednesday upped his price target to 50 pence from 25 pence.

It has been a tough year for Phytopharm. The stock has languished ever since a planned collaboration with Unilever NV (UNA.AE) to develop a Slim Fast diet drink based on the hoodia plant was called off last November.

Robin Davison, an analyst at Edison Investment Research, said Wednesday's share price rise shows investors are still interested in Phytopharm.

"The company has shown it still has a drug, where previously people had written them off," said Davison.

It might also signal renewed interest in the U.K. small-cap drug sector, which has suffered from a dearth of funds and several company failures, he added.

Company Web site: www.phytopharm.com

IMHO, ....you can forget the 4x jump in sp - it was the ONLY good news (any ?) we've had since the shares were 1....way back when they thought their product would cure obesity....can anyone remember how many years that was ago..
. . . . . . . . . . . . . . Clearly rubbish, it limps on . . . . . . . . . . . .

Now they have the nerve to build-up prospects of untold wealth on the basis of a phI result (ie it doen't kill you).....and this fundraising will be hugely dilutive.....

I really wonder if this isn't "...more of the same..." - - - I really object to phrases like "...potentially addresses a large and as of yet unmet medical need..." - this adds nothing to the effacy of their product, it is IMHO mere puff, or at worse it's ramping, - even before the Trials are mid-way. Not the expected PR from a full-list company.
=Grr.
FWIW, I note the Co says the money will be used for various operational uses as well as PhII trials - and the risk of failure is huge even from the start of PhII.
Maybe wait for the documents . . . .
DYOR

pym despite its problems in the past has huge potential for cognane - potential market of billions - so far trials gone well - also has other products - just need some more patience - personally i am going to give pym to end 2010 to improve sp with hopefully decent rns throughout the year - should reach 50p imo easily - slow share clinical trials etc take time - more patience needed - sorry for anyone who bought in 30p+ - i will be taking my 8 for 3 placement / open offer

gibby, are you sure - for there is "no evidence" ( ie "yet") that their product works.
However, there is evidence the sp has been pushed up prior to the RNS - and I don't like this - just review the volume from a week prior....

I accept yr timescale - "end-of2010" - in a year there should be some "news" - but it won't be very much to impress current holders who have been massivly diluted by this Offer.

Furthermore, I recall reading that when a stock is "hot" the City can raise all the funds req'd. Only when it might "stick" are the investors asked....

Maybe we'll have to Agree to Disagree; as I'm tempted to ignore this Attractive Offer.....and maybe put the money to a nice present to Me, like a 12MP digital Camera......and a nice holiday into the sun, before I can't move for Carbon-Permits.

hangon - i agree its a risk but arent all shares - i am actually only trading with pym from other share profits so if it goes belly up the worst i will do is off set the loss against my cgt - trust me i know pyms history so aware of risk, but invesco for as an example have taken up their full entitlement through their iaml vechicle & if its good enough for them + my research its good enough for me - they have also guaranteed to take up any oo shares not taken up by pi's i believe - but will see how 2010 goes - i am very confident but happy to eat huge slice of humble pie if i am wrong - any how i hope your dealing goes well and profitable where ever you may invest - pym are not my only investment - lots of opportunities out there as i am sure you are aware - GL

Presents data at XVIII WFN World Congress


GODMANCHESTER, Cambridgeshire, U.K. (14 December 2009) - Phytopharm plc (LSE: PYM) ("Phytopharm" or the "Company") announces that Dr Jonathan Brotchie will present data from a "gold-standard" non-clinical study of Cogane, a promising novel oral treatment for Parkinson's disease, at the 50th WFN World Congress on Parkinson's Disease and Related Disorders, which is taking place in Miami from 13 - 16 December.


The outcome of this study, an overall 43% decrease in parkinsonian symptoms over 18 weeks administration of Cogane, was first reported by Phytopharm on 14 October 2009 along with the results of a successful safety, tolerability and pharmacokinetic trial in healthy volunteers and patients with Parkinson's disease.


Dr Brotchie, a senior scientist at Toronto Western Hospital, who conducted the trials, is a recognised expert in the field of Parkinson's disease and runs one of the world's premier research laboratories for the identification of novel treatments, diagnostics and cures for Parkinson's disease and related disorders.

Isn't it heartening that so much good-news comes at a time when the company is diluting L-T investors and ripping-off new ones? Folk could have bought into this company at any time during the year when there was zippo on the Newsfront...? I wonder if the next 12-months will be a mirror...?

I didn't take-up my placing shares, 'cos I think we was manipulated....the sp graph says it all. See the peaking just days before the placing was ann.

DYOR and bear in mind that the trumpeted product Trial is years away from commercialisation....indeed they'll have to rejig their scratchless-doggy cream in preparation for a further round of Funding, not for Trials....but to service the gardens and upgrade the lawns at their country seat.
Hoodia . . . . I should Coco.
This has been a woeful investment.
EDIT (22Dec09)-up a tad, at 11.5p but Rights takeup is only 51% - yuk.
EDIT (28May2010)-down further today mkes me wonder if this isn't dead? Gibby hopes for a buy-out. Well Hoodia has shown no signs of success...and without that, what's left?
EDIT (22Jy2010)- Oh deary, Director lathered by Options of 1.7million at zero cost (for now), priced below today's price 8p.......exercisable for the next 5years (I thk).Win-Win or what? This stock is a disgrace IMHO.

hangon - you are semi correct - dont all companies manipulate the sp - some far worse than this - but your post is also amusing- i'm not worried if next stage goes well sp will impprove very much - wouldnt ne surprised if a major pharm eventually bought out ptm - probably why invesco have a large stake in pym through one of their subsidaries - until invesco naff off i will be staying - gl

Interim Management Statement.

Phytopharm receives USA regulatory approval to begin Phase II clinical trial of Cogane

About B*** time, I hear!
This outfit has long been resting in a sleepy Cambridge backwater. with only fields, sheep and cows to look at, oh and a large pond at the front. The sp has been a disaster whilst directors have prospered and come/gone.
-Meanwhile retail investors have no whiff of the "weight reduction" technology -(Hoodia)- so, I'm guessing it's dead and burried and explains why originally they were so keen to keep it "pharma" (read long delays before truth is out-DYOR), instead of releasing it as a healthfood which would almost certainly create an income....but then Directors don't want to be associated with such lowly products.
Their dog-scratchy cream was no success and whatever this(news today) is, it's ONLY PhII - grief, . . . . expect a further 5-years before retail shareholders see anything.
Currently abt 8p (was 1.40-ish some while ago . . . . Grief!)
All IMHO + DYOR

Ruddy Nerve!
The company is giving itself away to Execs - Options.
In the past year the sp has fallen from 11p to current 7.5p - Grief are these execs even "turning-up" - - - - - I see little for their cost, perhaps they've been busy painting the decking round the back.
Woof, Woof, -this is a Dog.
EDIT (10Jan11)- Up nearly into double figures(=8p) on some News that didn't make it to RNS - dunno, maybe they have stopped buying the local NewsPaper, saving 150 a year....it can't be important, can it? Yet Fido will still need some bedding...Woof, Woof.

I see this lot are still plugging away!

Half Yearly Report.

Phytopharm undertakes Parkinson's disease study

RNS Number : 2232L

Phytopharm PLC

27 July 2011

28 July 2011


Company Contact: U.K. Investor Relations
Phytopharm plc Contact:
Tim Sharpington CEO FD
Roger Hickling R & John Dineen
D Director Ben Atwell
+44 1480 437 697 +44 207 831 3113
www.phytopharm.com

Cogane(TM) - US FDA Grant Orphan Drug status for treatment of ALS

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the United States Food & Drug Administration (US FDA) has granted Orphan Drug status to Cogane(TM) (PYM50028) for the treatment of amyotrophic lateral sclerosis (ALS).

ALS, also known as Lou Gehrig's disease, is the most prevalent form of motor neurone disease, which generally strikes people between 40 and 60 years of age. It is characterised by progressive loss of both lower (spinal cord and brain stem) and upper (cerebral cortex) motor neurones, which leads to severe muscle weakness and wasting, followed by paralysis and death, generally caused by respiratory failure. There is an urgent need for the development of new approaches to this devastating condition. There are estimated to be 20-30,000 people with ALS in the United States with approximately 5,600 new cases diagnosed each year. For a product to gain orphan drug status in the United States, the condition must affect less than 200,000 people in the United States.

As reported in the Company's Interim Results, Cogane(TM) has previously shown promising activity in preclinical in vitro and in vivo models of ALS. A study of Cogane(TM) in the genetic "gold standard" in vivo model of ALS is ongoing. This study has the support of the Motor Neurone Disease Association, a UK based charitable organisation, which has provided a grant to cover the costs of the study. Results from the study are expected in Q4 2011 and, if positive, offers the potential to support a rapid progression into clinical trials of ALS.

Research Update.

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that the European Commission has granted Orphan Drug status to Cogane (PYM50028) for the treatment of amyotrophic lateral sclerosis (ALS).

The United States Food & Drug Administration (US FDA) granted Orphan Drug status to Cogane (PYM50028) for the treatment of amyotrophic lateral sclerosis (ALS) in July 2011

ALS, also known as Lou Gehrig's disease, is the most prevalent form of motor neurone disease, which generally strikes people between 40 and 60 years of age. It is characterised by progressive loss of motor neurones, which eventually leads to death. There is an urgent need for the development of new approaches to this devastating condition. It is estimated that the prevalence of ALS in Europe is 0.5‑1.1 per 10,000. For a product to gain orphan drug status in Europe, the condition must affect less than 5 in 10,000 people in the member states.

As reported in the Company's Interim Results, Cogane has previously shown promising activity in preclinical in vitro and in vivo models of ALS. A study of Cogane in the genetic "gold standard" in vivo model of ALS is ongoing. This study has the support of the Motor Neurone Disease Association, a UK based charitable organisation, which has provided a grant to cover the costs of the study. Results from the study are expected in Q4 2011 and, if positive, offer the potential to support a rapid progression into clinical trials of ALS.

Research Update.

Phytopharm is Awarded a Technology Strategy Board Grant to Support the Development of Myogane in Glaucoma
Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm" or the "Company") today announces that it has been awarded a grant by the Technology Strategy Board to provide funding to support the evaluation of Myogane in an in vivo preclinical model of glaucoma.
Myogane has the potential to be a neuro-protectant treatment of glaucoma. Glaucoma is a neurodegenerative disease of the eye affecting 60 million people and is the second leading cause of blindness worldwide. Current treatments of glaucoma are predominantly targeted at reducing intra ocular pressure within the eye, however the remains a major unmet medical need for treatments which can slow the underlying neurodegenerative disease process.

Myogane has demonstrated neuro-protective and neuro-restorative effects in a range of neuronal cell types including retinal ganglion cells, which are the cells affected in glaucoma. Myogane exhibits it's effect via the modulation of neurotrophic factors, naturally occurring proteins which protect and promote the growth of neurones and which have been shown to be effective in protecting against neurodegeneration in a number of models of glaucoma.

The study, if positive, will support the further clinical development of Myogane in glaucoma. Myogane is a small molecule drug which has been shown to have good oral bioavailability when dosed once daily in Phase I studies.

Despite the woeful sp, I'm thinking that maybe (only Maybe!) this is showing signs of potential.
EDIT. Ooops, sorry a lorry-load of chimps has taken over my keyboards...
EDIT 26March2012, AGM tomorrow, shan#t go as it's just too tedious welcoming new faces to the Board, who replace other faces that were welcomed a while back. Still this is buzzing about, waiting to land on the fly-paper one suspects . . . a long slow and painful future awaits..... all IMHO. Grr.

Annual Financial Report.

Directorate Change.

Interim Management Statement.

Highlights for the period
· Cogane™ demonstrated efficacy in a genetic preclinical model of amyotrophic lateral sclerosis (ALS).
· Dr Ian Tulloch, former Global Product Marketing Director at Novartis Pharma AG appointed as a Non-Executive Board Director. Dr Tulloch will succeed Mr Sandy Morrison who will step down as a Non-Executive Board Director following the Company's 2012 Annual General Meeting.
· Recruitment of patients with Parkinson's disease (PD) into the multi-national Cogane™ Phase II dose ranging study (CONFIDENT-PD) is ongoing.

Confirmatory data supports effectiveness of Cogane™ in
Amyotrophic Lateral Sclerosis

This time?

Interim Management Statement

Maybe this time?

preliminary Results

Business highlights

Operational

· Recruitment into CONFIDENT-PD Phase II clinical trial of Cogane™ in untreated patients with early stage Parkinson's disease was completed in April 2012 and the last patient is expected to complete the trial in late November 2012. Headline results from the trial remain on track to be available in February 2013.

· Cogane™ demonstrated efficacy in the "gold standard" preclinical model of amyotrophic lateral sclerosis ("ALS"), the most common form of motor neurone disease. Positive data have now been obtained in four models of ALS, providing a strong rationale for Cogane™ as a potential treatment for this devastating condition.

· A Phase I clinical trial to evaluate Cogane™ solid dose oral formulations for up to 28 days has been initiated.

· A study of Myogane™ in a preclinical model of glaucoma was inconclusive due to an unexpectedly low neuronal cell loss in the control group which prevented evaluation of a neuroprotective effect of Myogane™.

Corporate

· Dr Ian Tulloch was appointed as a non-executive Board director in February 2012. As planned, Mr Sandy Morrison stepped down from the Board following the Company's Annual General Meeting in March 2012.


Financial
· Loss after tax of £7.77 million in line with expectations reflects ongoing focus on the development of our pharmaceutical programmes (2011: £7.66 million).

· Cash and money market investments of £8.89 million (2011: £17.57 million). Based on our current expectations Phytopharm is financed to at least the end of Q1 2014.

Looks like the rumour mill is active.

Still quiet skinny,not even a mill traded so just mm playing games been watching all day.

Still have up tp 8 weeks or so before i jump on board......

Will get a new thread up and running soon as one to keep an eye on.

Coincidence?

COGANE™ IN ALS UPDATE

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group", or the "Company") today announces an update on plans for the further clinical development of CoganeTM as a potential treatment for Amyotrophic Lateral Sclerosis ("ALS").
Earlier this year the Company announced the successful completion of the preclinical evaluation of Cogane™ in ALS, which provided strong support for progression into clinical trials in this indication. Subsequently the Company has been working with a number of leading opinion leaders and charities with an interest in ALS to design a clinical development plan for Cogane™ in ALS.

As part of this process two leading grant-giving bodies, the ALS Association ("ALSA") and the North-East ALS Consortium ("NEALS") in conjunction with Massachusetts General Hospital, have provisionally indicated that they will provide financial and logistic support for future studies of Cogane™ in ALS. Both of these grants are contingent on the Company moving forward with a study in ALS.

The Company is also in discussion with leading regulatory agencies with regard to the design of a clinical development plan for Cogane™ in ALS.

Interim Management Statement

During the period

· The last patient completed participation in the CONFIDENT-PD Phase II clinical trial of Cogane™ in untreated patients with early-stage Parkinson's disease in December 2012. Results from this trial remain on track to be available in February 2013.

· Further work is ongoing with a number of leading opinion leaders and charities with an interest in Cogane™ in Amyotrophic Lateral Sclerosis ("ALS") to design a clinical development plan. Provisional indications for financial and logistical support for future studies of Cogane™ as a treatment for ALS have been received.

· A meeting has been held with the US Food and Drug Administration ("FDA") at which a clinical development plan for Cogane™ in ALS was agreed. Cogane™ for ALS has been granted Orphan Drug status which offers the potential for accelerated development compared with conventional drug development programs.

· A Phase I study of new solid dose formulations of Cogane™ was initiated and results are expected in Q1 2013.

· Our financial performance from 1 October 2012 to date continues to be in line with our expectations. Based on our current expectations Phytopharm is financed until at least the end of Q1 2014.

Last postings were a bit too optimistic . . and confused, some say - "...Despite the woeful sp, I'm thinking that maybe (only Maybe!) this is showing signs of potential.
EDIT. Ooops, sorry a lorry-load of chimps has taken over my keyboards...
EDIT 26March2012, AGM tomorrow, shan#t go as it's just too tedious welcoming new faces to the Board, who replace other faces that were welcomed a while back. Still this is buzzing about, waiting to land on the fly-paper one suspects . . . a long slow and painful future awaits..... all IMHO. Grr.

Todays failure of the Parkinson's Drug [ RNS- DYOR], is just another failure for this Co . . . . I say:- "Get on with something that makes a profit . . . . and leave cutting-edge research to the professionsals . . . selling doggy-cream wasn't your bag either, so make it something easy, eh?"

ooops! "Analyst Paul Cuddon at Peel Hunt said the result was a conclusive failure for Phytopharm's key asset, and he attributed no value to the group's remaining pipeline of drugs."

one for the dustbin

Yes looks that way!

Strategic Review Update

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", the "Group" or the "Company") today announces an update on the on-going strategic review which was initiated following the announcement of headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease. The update will also be provided to shareholders attending the Company's AGM today.

On the 18th February Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. A full analysis of the complete dataset has now been completed which confirms the initial view that no efficacy was demonstrated in the primary or secondary endpoints measured in the study.

As a result of these findings no further research and development expenditure will be committed and a staff reduction and cost saving programme has been initiated.
After discussions with major shareholders the Board has initiated a review of the strategic options available to the Company which includes the review of a number of merger and acquisition opportunities. Exploratory discussions have been held with a number of parties and further updates will be made as appropriate.

Re: Suspension of Trading


On the 18th February 2013 Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. After discussions with the Company's major shareholder the Board initiated a review of the strategic options available to the Company, including a review of a number of merger and acquisition opportunities. Further to this, the Board of Phytopharm is pleased to announce that Phytopharm has recently signed heads of terms in connection with the possible acquisition of a revenue generating UK based private company in the healthcare sector ("Target").



The transaction would be structured by way of an acquisition of the Target by Phytopharm in consideration for the issue of new Phytopharm shares to the shareholders of the Target. Due to its size in relation to Phytopharm, the proposed acquisition of the Target constitutes a "reverse takeover" for the purposes of the Listing Rules. At the request of the Company, trading in Phytopharm's Premium listed shares on the Main Market of the London Stock Exchange ("Main Market") has been suspended by the UK Listing Authority pending publication of the required shareholder documents. Shareholder approval would be required to approve the acquisition of the Target which would be sought at a general meeting to be convened in due course, after which the Company also expects to delist from the Main Market and seek admission of the enlarged share capital to trading on AIM.



The Board expects to make a further announcement in due course.

Interim Results

Financial summary

· No further research and development expenditure has been committed and a staff reduction programme has been put in place.

· Loss after tax of £2.65 million (HY 2012: £4.88 million).

· Cash and money market investments of £6.33 million (HY 2012: £13.33 million; FY 2012: £8.89 million).

Yes, but what of the Co Ann of 21 May 2013? (Post No 84)- Does this say that PYM is being taken over? . . .not how I read it "Target" seems to be the other way, ie PYM is taking over a larger company - Eh?
...I could just wait and see...

From the link in post 85 :-

"On the 18 February 2013 Phytopharm announced that analysis of the headline results from its Phase II clinical trial of Cogane™ in Parkinson's disease indicated that the drug had not demonstrated clinically meaningful efficacy. After discussions with the Company's major shareholder the Board initiated a review of the strategic options available to the Company, including a review of a number of merger and acquisition opportunities. Further to this, the Board of Phytopharm is pleased to announce that Phytopharm has recently signed heads of terms in connection with the possible acquisition of a revenue generating UK based private company in the healthcare sector ("Target").

The transaction would be structured by way of an acquisition of the Target by Phytopharm in consideration for the issue of new Phytopharm shares to the shareholders of the Target. Due to its size in relation to Phytopharm, the proposed acquisition of the Target constitutes a "reverse takeover" for the purposes of the Listing Rules. At the request of the Company, trading in Phytopharm's Premium listed shares on the Main Market of the London Stock Exchange ("Main Market") was suspended on 21 May 2013 by the UK Listing Authority pending publication of the required shareholder documents. Shareholder approval would be required to approve the acquisition of the Target which would be sought at a general meeting to be convened in due course, after which the Company also expects to delist from the Main Market and seek admission of the enlarged share capital to trading on AIM. The Company expects to make a further announcement in due course."

Of course, this is the reward investors can expect having invested in the exciting tech placed in the Public Domain by the Company . . . the shares in ISA/and PEP before) being considered unworthy.
Well thanks PYM; it's good to know the Directors have retained their seats and continue to enjoy a good life, pension and happy meals.
"Rot in . . ." springs to mind.


Tech carries risk, but it should be shared by all - and I don't see why they need to delist from the main market, other than to boost a notional improvement from their new start. Snag is they still have the same dreary captains at the Helm, each pulling in different directions, no doubt.

Proposed acquisition of IXICO Limited
Proposed Issue of up to 8,479,753 New Ordinary Shares in the Company
Proposed change of name to IXICO plc
Admission of the Enlarged Issued Share Capital to trading on AIM
Renewal of Shareholder Authorities
and
Notice of General Meeting

Phytopharm plc (PYM: London Stock Exchange) ("Phytopharm", or the "Company") today announces that terms have been agreed for the conditional acquisition (the "Acquisition") of IXICO Limited ("IXICO"), a medical technology and diagnostics company. The aggregate consideration for the Acquisition is to be satisfied by the initial issue of 8,014,403 New Ordinary Shares on Admission and the proposed issue of 465,350 New Ordinary Shares as a result of the outstanding share options under the IXICO unapproved share option share scheme. Based on the Phytopharm closing share price of 20 May 2013 immediately prior to its suspension, the aggregate consideration is valued at approximately £5.6 million.

Following completion, it is expected that Phytopharm shareholders will own approximately 45 per cent and that IXICO shareholders will own approximately 55 per cent of the Fully Diluted Enlarged Issued Share Capital. In view of the size of IXICO in relation to the Company, the Acquisition is classified as a reverse takeover under the AIM Rules and is therefore conditional, inter alia, on the approval of Shareholders in a general meeting. A copy of the admission document along with the notice of General Meeting is being sent out to shareholders shortly and will be available on the Company's website www.phytopharm.com.

The Directors of Phytopharm consider that IXICO will provide a platform from which to create value for Shareholders and will provide a different risk profile to the Company's business model. Upon completion of the Acquisition, Phytopharm plc will change its name to IXICO plc with the new ticker "IXI".

IXICO expands into digital healthcare

Portfolio company IXICO expands into digital healthcare

Imperial Innovations Group plc (AIM: IVO, "Innovations") portfolio company IXICO Limited, a medical imaging analysis company, is to be acquired by Phytopharm plc (AIM: PYM) in a proposed reverse takeover announced today. The enlarged Phytopharm group, to be renamed IXICO plc, will benefit from a strengthened balance sheet to grow its clinical trial services business and to bring new technology solutions to the diagnosis of dementia and other conditions. The newly-quoted IXICO plc will use the new ticker 'IXI'.

Innovations maintains its support for IXICO and as part of this transaction has purchased a small parcel of shares; following completion of this transaction it will hold a 11.518% shareholding in IXICO plc.

IXICO has established itself as a leading provider of medical imaging analysis services in the clinical trials market. It is expanding into the 'digital healthcare' space with products to support dementia diagnosis. Its vision is to build on its credibility internationally to position itself as a 'Brain Health Company' and to bring innovative technologies to those involved in researching and treating serious brain diseases enabling them to help patients more quickly.

Maina Bhaman, Director of Healthcare Ventures at Innovations, will be joining the IXICO plc board on completion.

Restoration - Phytopharm Plc

24/09/2013 7:30am

RESTORATION OF TRADING ON AIM

PHYTOPHARM PLC

The trading on AIM for the under-mentioned securities was temporarily suspended. The suspension is lifted from 24/09/2013 7:30am, the company having published an admission document.

Ordinary shares of 50p each, fully paid (BCLY7L4) (GB00BCLY7L40)

If you have any queries relating to the above, please contact the company's nominated adviser on 020 7418 8900.

DYOR - Odd that I can't see any mention of [PYM] in the Newsflow from AIM-listed [IVO].
. . . has someone forgotten to tell?



Oh deary PYM, rip

Shareholder Information

The current incarnation of PYM on the up.